Company intelligence / Profile preview

ChronTech Pharma AB

Stockholm, Sweden

Ownership: Private
Development stage: Phase 2

Overview

ChronTech developed therapeutic DNA vaccines against chronic hepatitis C and B. Their ChronVac-C study showed the vaccine was safe and provided positive clinical data. Five of six patients who completed the ChronVac-C study and then started standard treatment showed rapid viral response, indicating a potential role for ChronVac-C in combination therapy[2]. A controlled phase II clinical study of ChronVac-C in combination with standard-of-care was expected to report results in Q1 2013[3].

Therapeutic areas: DermatologyInfectious Diseases
Modalities: DNA vaccinestherapeutic vaccines
Industry: Biotech

Drug pipeline

1 asset

ChronVac-B

Discontinued

Partnerships

Inovio PharmaceuticalsTransgeneKringle Inc. (Japan)Opsonic Therapeutics

Beyond the preview

Go deeper on ChronTech Pharma AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChronTech Pharma AB.

Explore the full profile